NEW YORK (GenomeWeb News) – PerkinElmer announced today that it has purchased several radiochemical-related reagent assets from GE Healthcare.

Under the agreement, PerkinElmer will obtain GE Healthcare's 3H and 14C catalog radiochemicals, along with its Scintillation Proximity Assay (SPA) reagents and Cytostar-T plate product lines.

Catalog radiochemicals are used for a variety of research purposes including binding assays that may reveal possible drug candidates. The SPA and Cytostar-T plate products, meanwhile, allow high-throughput screening for such interactions.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.